Enhanced surveillance of hepatitis B and C in the EU/EEA

Erika Duffell, Hepatitis Expert
European Centre for Disease Prevention and Control
Stockholm, 2nd Hepatitis B and C Network Meeting, 17 April 2013
Once again I would like to apologise for not being able to attend the meeting

I do have some ready prepared slides on the data collected through the enhanced surveillance system for 2006 – 2011 data that I presented at the Network meeting in April. You are most welcome to use these slides but the key issue to emphasize is that the data are weak with severe limitations as highlighted in the report – with data more reflective of testing and differences in surveillance than the underlying epidemiology (with perhaps the exception of acute hepatitis B) – see enclosed report.

With regards

Erika
Outline of the presentation

• Overview of enhanced surveillance programme for hepatitis B and C across EU/EEA countries
• Results from 2006 to 2011 data collection
• Summary of the key issues from the data collection
• Outline of the next steps for surveillance
Enhanced surveillance of hepatitis B & C

- European Commission and the Founding Regulation (2005) provide a strong mandate for surveillance of communicable diseases within the EU/EEA
- ECDC coordinates the enhanced surveillance of hepatitis B and C across EU/EEA countries
- A Coordination Group was set up in 2010 to oversee the implementation of enhanced surveillance
- First meeting of the European Network for Hepatitis B and C surveillance in March 2011
- Revised case definitions presented to EU Network Committee September 2011
Enhanced surveillance of hepatitis B & C
- Specific objectives

1. Collect all newly diagnosed and reported cases of hepatitis B and C
2. Distinguish between different presentations (acute/chronic)
3. Describe the prevalence of infection in the general population and in populations at high risk for infection
4. Identify health care acquired infections
5. Monitor hepatitis B and C related morbidity and mortality
## Enhanced surveillance of hepatitis B & C - Variables

<table>
<thead>
<tr>
<th>Type</th>
<th>Variable Name</th>
<th>Mandatory</th>
<th>Hepatitis B</th>
<th>Hepatitis C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Core set</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>RecordId</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>RecordType</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>RecordTypeVersion</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Subject</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>DataSource</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>ReportingCountry</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>DateUsedForStatistics</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Status</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>DateOfNotification</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>DateOfDiagnosis</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PlaceOfResidence</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>PlaceOfNotification</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Age (years)</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Gender</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>DateOfOnset</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Outcome</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Classification</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Disease specific</td>
<td>StageHEP</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>ResultHBsAg</td>
<td>N</td>
<td>✓</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>TestingLocation</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>CountryOfBirth</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>CountryOfNationality</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Imported</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>ProbableCountryOfInfection</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Transmission</td>
<td>Y</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>SexWorker</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>HealthCareWorker</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>HIVStatus</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>HBVStatus</td>
<td>N</td>
<td>✓</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>HCVStatus</td>
<td>N</td>
<td>✓</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>VaccStatus</td>
<td>N</td>
<td>✓</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>Complications</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>Genotype</td>
<td>N</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>
Enhanced surveillance of hepatitis B & C
- Principles

• Data from Member States is uploaded into the European Surveillance System (TESSy)
  - TESSy was created according to ECDC’s founding regulation for the reporting of routine surveillance data

• Case-based and aggregate reporting of data possible

• Data will be collected on a yearly basis after initial two data collections:
  1. 2006-2010 data collected December 2011-January 2012
  2. 2011 data collected September - October 2012
Results from first data collections
Hepatitis B

28 countries provided hepatitis B data in 2011
• 14 countries could only provide data on acute cases

Case definitions varied:
• 18 countries used the revised EU case definition
• 6 countries used the EU 2008/EU 2002 case definitions
• 4 countries used national case definitions

24 countries were able to classify cases as acute or chronic using the stageHEP variable
Results from first data collections
Data completeness in 2011

- Transmission
- Testing location
- ‘StageHEP’
- Sex worker
- Probable country of infection
- Outcome
- Imported
- HIV status
- Health care worker
- Genotype
- Gender
- Country of nationality
- Country of birth
- Complications
- Age

Data completeness (%)

Hepatitis C
Hepatitis B
Key issues from first data collection
Hepatitis C

26 countries provided hepatitis C data in 2011
- 5 countries could only provide data on acute cases

Case definitions varied:
- 15 countries used the revised EU case definition
- 7 countries used the EU 2008 case definition
- 4 countries used national case definitions

13 countries were able to classify cases as acute or chronic using the stageHEP variable
Results from first data collection
Hepatitis C

• In 2011, 29 896 hepatitis C cases were notified:
  – 398 (1%) Acute
  – 2913 (10%) Chronic
  – 24 337 (81%) Unknown

• Variation in overall numbers and rates between countries
  – Rates of reported acute infections ranged from <0.1 in Portugal, Hungary and Ireland to 2.0 in Austria
  – Rates of reported chronic infections ranged from 0.1 in Greece to 14.0 in Estonia

• Among countries with consistent reporting of acute and chronic cases between 2006 and 2010 there were fluctuating trends
Acute and chronic hepatitis C cases in EU/ EEA countries, 2006-2011
Number per 100000 population

Source: Country reports from countries with consistent reporting of acute and chronic infections between 2006 and 2011 (Denmark, Estonia, Slovakia, Slovenia).
Results from first data collection
Hepatitis C

• Just over half of all cases were aged between 25 and 44 (54% cases)
  – 11% were aged under 25
• The overall male to female ratio was 2:1
• Transmission mode (29% complete):
  – Acute: Injecting drug use (33%); nosocomial (17%); men who have sex with men (24%)
  – Chronic: Injecting drug use (84%); nosocomial (5%); blood and blood products (3%)
• The migration variables were poorly reported but implied that migration contributes towards hepatitis C infections in Europe but this is less significant than for hepatitis B
Reported total hepatitis C cases in 2011*

Number per 100 000 population

- < 5
- 5.0 - 14.9
- 15.0 - 54.6
- No data
- Non EU/EEA countries

*Countries included if their surveillance systems captured data on both acute and chronic cases.
Anti-HCV prevalence among pregnant women

Key limitations of the data

- Many countries only collect data on **acute** hepatitis cases
- Difficulties with defining cases using **StageHEP** criteria
  - Many cases (especially hepatitis C) coded as unknown
  - Some countries used their own criteria
- Data **completeness** low (<10%) for certain variables:
  - Genotype, complications, country of nationality, HCV status (for HBV cases), HBV status (for HCV cases), HIV status, sex worker, healthcare worker
- **Under-reporting** in some countries
  - Estimated by France to be as high as 85% for acute hepatitis B cases
- **Changes** in reporting practice **over time**
- Different **case definitions** used by countries
Summary of key findings

• High numbers of reported hepatitis B and C cases across Europe
  – Cases of hepatitis C double those of hepatitis B
  – Chronic cases dominate across both diseases
  – Variation between countries
• For hepatitis B figures suggest a decrease in acute cases and a rise in newly reported chronic infections
• For hepatitis C, there is a strong geographical trend
• Transmission routes for hepatitis B differ from hepatitis C, and for hepatitis B these routes varied by disease status
• Imported cases are significant, especially for chronic hepatitis B infections
Next steps for enhanced surveillance

• Report on 2006 – 2011 data will be published around World Hepatitis Day in July 2013
• Collection of 2012 data during summer/autumn 2013
• Further discussions around surveillance in working groups
  - Case definitions
  - Alternative methods of surveillance
  - Surveillance outputs
• Possibly: Meeting of a hepatitis surveillance working group later in 2013
Acknowledgements

Thank you to the following groups and individuals:

• The European Hepatitis B and C Network and Coordination group.

• All EU/EEA country hepatitis and surveillance contact points.

• Surveillance colleagues at ECDC - Lucia Pastore Celentano, Phillip Zucs, Denis Coulombier, Andrew Amato, Valentina Lazdina, Gaetan Guyodo, Aidan Prodan, Frantiska Hruba, Catalin Albu.

• Colleagues in the programme on STI, including HIV/AIDS and bloodborne viruses: Marita van de Laar, Gianfranco Spiteri, Dragoslav Domanovic, Caroline Daamen, Giedrius Likatavicius, Anastasia Pharris, Otilia Sfetcu, Teymur Noori, Karin Haar, Luisa de Leo.